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Poststroke depression is one of the major symptoms observed in the chronic stage of brain stroke such as cerebral ischemia. Its
pathophysiological mechanisms, however, are not well understood. Using the transient right middle cerebral artery occlusion-
(MCAO-, 90min) operated rats as an ischemia model in this study, we first observed that aggravation of anhedonia spontaneously
occurred especially after 20 weeks of MCAO, and it was prevented by chronic antidepressants treatment (imipramine or
fluvoxamine).The anhedonia specifically associated with loss of the granular neurons in the ipsilateral side of hippocampal dentate
gyrus and was also prevented by an antidepressant imipramine. Immunohistochemical analysis showed increased apoptosis inside
the granular cell layer prior to and associated with the neuronal loss, and imipramine seemed to recover the survival signal rather
than suppressing the death signal to prevent neurons from apoptosis. Proliferation and development of the neural stem cells were
increased transiently in the subgranular zone of both ipsi- and contralateral hippocampus within one week after MCAO and then
decreased and almost ceased after 6 weeks of MCAO, while chronic imipramine treatment prevented them partially. Overall, our
study suggests new insights for the mechanistic correlation between poststroke depression and the delayed neurodegenerative
changes in the hippocampal dentate gyrus with effective use of antidepressants on them.
1. Introduction
Transient focal cerebral ischemia is the most common type
of stroke caused by occlusion of a cerebral artery [1]. It causes
both acute and chronic dysfunctions in the central nervous
system (CNS) and lowers the quality of life in patients
for a long period of lifetime. The middle cerebral artery
(MCA) is most frequently infarcted in the cerebral ischemia,
and various animal models have been developed including
nonhuman primates and rodents [2, 3]. In the models of
transient focal cerebral ischemia, neurons in the ischemic
core including cerebral cortex and some parts of the striatum
were immediately damaged after the ischemia-reperfusion
manipulation, sometimes followed by the delayed neuronal
death in the areas apart from the ischemic core, including
a part of thalamus, substantia nigra, and hippocampus
[4–6]. They cause various dysfunctions such as cognitive,
mood/emotional, and motor impairments in the chronic
stage after stroke.
Among the CNS dysfunctions in the chronic stage of
cerebral ischemia, depression is one of themajor mood/emo-
tional impairments known as poststroke depression (PSD). It
has been generally recognized that PSD occurred in around
40% of the stroke patients [7, 8], although it varies depending
on the studies from around 20% [9] to 72% [10]. Because the
physical disabilities lowering the activities of daily living are
the stressor on the stroke patients, PSD has been believed
to occur as the result of psychogenic and systemic responses
to the stressed conditions with complicated mechanisms of
pathogenesis [11]. Robinson and Price reported their follow-
up study of 103 stroke patients with evaluating PSD [12,
13], confirming that the lesion location (frontal area in
the left hemisphere and posterior area in the right hemi-
sphere) determined frequency and severity of depression.
It was the first study suggesting the PSD pathogenesis as
a neurodegenerative lesion in a particular brain area. Now,
PSD pathogenesis is considered to be multifactorial with
neurodegenerative, psychogenic, and genetic mechanisms.
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Animal models of PSD have been reported especially using
rodents [14], mostly combining a surgical operation (MCA
occlusion) with application of extra stressors such as unpre-
dicted chronic mild stress (UCMS) [15, 16], ovariectomy [17],
and spatial restraint stress [18].
Among various symptoms seen in PSD, anhedonia is one
of the typical ones: loss of interest or pleasure in almost all the
activities and things that one previously liked [19]. Pathogen-
esis of anhedonia includes brain areas such as orbitofrontal
cortex, nuclear accumbens, and ventral pallidum. A recent
study reported a positive correlation between the postis-
chemic anhedonia with salivary cortisol levels and reduction
of volume by lesion in parahippocampal/hippocampal area
[20].
Hippocampus is one of the vulnerable areas to the
ischemic stress, showing delayed neuronal death in CA1
region within a few days to a week after MCA occlusion
(MCAO) [6, 21, 22]. Because hippocampus is deeply related
to higher brain functions such as cognition, learning, and
memory, CA1 degeneration causes functional impairments
of them after stroke. Different from CA1, other regions such
as CA3 and dentate gyrus (DG) in the hippocampus are
considered to be resistant to the ischemic stress [23, 24]. The
neurogenesis in subgranular zone (SGZ) of DG as well as
cortical subventricular zone (SVZ) produces newly generated
neurons even in adulthood and is known to increase neu-
ral stem cells (NSCs) proliferation and differentiation into
neurons after the transient brain ischemia [25, 26]. Because
the rats that received UCMS after MCAO treatment had
reduced neurogenesis in DG, it was considered as an adaptive
or a compensatory process against the poststroke stressors
[15]. Proliferation and differentiation of NSCs in SGZ are
controlled by various factors such as stress, mood/emotion,
environment, corticosteroids, and antidepressants [27, 28].
Based on these backgrounds, we initially examined
whether anhedonia could be spontaneously induced after
MCAO in rats while observing them for up to 30 weeks
together with the effects of antidepressant imipramine (IMP)
or fluvoxamine (FLV) in this study.The reason why we chose
anhedonia rather than other depression-related behaviors
such as the forced swimming or tail suspension was to
minimize the negative effects of the motor impairments
directly influenced by MCAO. We also evaluated the long-
term neurodegenerative changes of the hippocampal DG,
including apoptosis of the granular cells (GC) and the
neurogenesis in SGZ, with the effects of IMP.
2. Materials and Methods
2.1. Experimental Animal. Youngmale SD ratsweighing 200–
250 g at 6 weeks of age were purchased from Nihon SLC,
Co., Shizuoka, Japan. They were housed in a controlled
environment (23 ± 1∘C, 50 ± 5% humidity) and were allowed
food and tap water ad libitum and habituated for 2 weeks
before the surgical operation. The room lights were on
between 8:00 and 20:00 (illuminated with 950 lux). The
procedure of the surgical operations for transientMCAOwas
described in our previous publications [22, 29–31]. In brief,
the right middle cerebral artery of the rat was occluded for
90min by inserting a silicone-coated 4-0 monofilament after
the right carotid artery was exposed and separated into the
internal and the external ones with careful conservation of
the vagus nerve under anesthetization with 2% halothane in a
mixture of 30% oxygen and 70% nitrous oxide. One day after
the reperfusion of blood flow by withdrawing the filament,
animals that showed grade 3 or over of Hunter’s neurological
score [32] were used for further experiments. To examine
the behavioral changes after the surgical operation for 30
weeks, 40 rats were divided into 4 groups: sham, sham +
antidepressants, MCAO, and MCAO + antidepressants (𝑁 =
10/group, total 𝑁 = 40). For the immunohistochemical
examinations, another 80 rats were divided equally into two
groups of sham and MCAO, and 5 rats/group were sacrificed
at 1 day (1 d), 3 days (3 d), 1 week (1 w), 2 weeks (2 w), 6 weeks
(6w), 20 weeks (20w), and 30 weeks (30w) after the surgical
operation. Na¨ıve animal (𝑁 = 5) means the rats fixed without
any surgical operation at 8 weeks of age.
All handling and procedures of animal experiments were
performed in accordance with the National Institutes of
Health Guide for the Care and Use of Laboratory Animals
(NIH Publications number 8023, revised 1978) and approved
by the Committee for Animal Experiments of Tokushima
University.
2.2. Antidepressant Treatment. From 1 week after MCAO,
the antidepressant imipramine hydrochloride or a selective
serotonin reuptake inhibitor (SSRI) fluvoxamine maleate
(Sigma, St. Louis, MO, USA) was dissolved directly in tap
water based on the daily amount of water consumption so
that the rats could absorb the drugs with 20mg/kg/day. The
doses were determined based on the previous reports [33–
36]. For drug administration, we avoided a direct handling
procedure such as intraperitoneal injection to minimize any
noxious stressor on rats after MCAO.
2.3. Sucrose Preference Test. This test is to evaluate anhedonia,
one of indices of depressiveness [37]. For habituation during
one week before MCAO, animals were exposed to water con-
taining 1% sucrose twice for 2 successive days separated by a
2-day interval substituted by normal tap water.The tests were
performed at 1 w, 2 w, 6w, 20w, and 30w after MCAO during
the dark period (20:00–8:00) with presenting two bottles
of water simultaneously (one was normal while the other
one contained 1% sucrose), and the percentage of sucrose
preference was calculated as (sucrose water intake)/(total
water intake).
2.4. Open Field Test. This test was performed to evaluate the
spontaneous activity of the rats at 1 w, 2 w, 6w, 20w, and 30w
after MCAO. The rats were put in an open field (50 cm ×
50 cm, divided into 25 squares of 10 cm × 10 cm by line grids)
under the 950-lux illumination for 10min and were recorded
by a video camera set at 60 cm high above the field. The
number of stepping instances over the grids was counted as
the horizontal activity, and the number of rearing instances
was counted as the vertical activity, by an examiner unaware
of the grouping details.
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2.5. Immunohistochemistry. The procedure of the immuno-
histochemical examinations was followed essentially by the
previous studies in our laboratory [22, 29–31]. Rats were anes-
thetized with intraperitoneal injection of 50mg/kg of sodium
pentobarbital solution at 1 d, 3 d, 1 w, 2 w, 6w, 20w, and 30w
after MCAO, flashed with 1% heparin-containing saline, and
fixed with perfusion of 4% paraformaldehyde (Wako, Osaka,
Japan) in phosphate buffered saline (PBS, pH 7.4, 137mM
NaCl, 2.7mM KCl, 10mM Na
2
HPO
4
, and 10mM KH
2
PO
4
).
One day after the fixation, brains were excised out and kept
in the same fixative solution for one night. The fixed brains
were washed with PBS for 1 hr × 3 times and dehydrated in
ethanol (70, 80, 95, and 100%) and then embedded in paraffin.
The coronal sections of the dorsal hippocampus (between
bregmata −2.5mm and −4.5mm) with 5𝜇m thickness were
sliced out by a sliding microtome (TU-213, Yamato, Saitama,
Japan), and 4 slices/animal (for one primary antibody) were
taken out from each of the 0.5mm ranges and mounted on
the slide glasses. For deparaffinization, the slices were heated
at 59∘C for 1 hr, treated with xylene, ethanol, and dH
2
O,
and then served for the immunohistochemical examinations.
Theywerewashedwith PBS for 3min× 3 times and incubated
with the blocking solution containing 10% normal horse
serum (Vector Labs, CA, USA) and 0.3% Triton X-100 in PBS
for 60min at room temperature.
For the primary antibodies of immunostaining, anti-
neuronal nuclei (NeuN, monoclonal, Chemicon-Millipore,
CA, USA, 1 : 200), anti-𝛽III-tubulin (monoclonal, Abcam,
MA, USA, 1 : 400), anti-MAP2 (monoclonal, Abcam, MA,
USA, 1 : 1500), anti-Bax (polyclonal, Santa Cruz, CA, USA,
1 : 100), anti-Bcl-2𝛼 (monoclonal, Lab Vision, ND, USA,
1 : 50), anti-Nestin (monoclonal, Chemicon, CA, USA,
1 : 500), anti-Ki67 (polyclonal, Abcam, MA, USA, 1 : 400),
and anti-doublecortin (DCX, polyclonal, Abcam, MA, USA,
1 : 1000) were used.Theywere diluted in the blocking solution
and incubated with the slices for one night at 4∘C. The slices
were washed with PBS for 3min × 3 times before incubating
with the secondary antibody. To visualize the bound primary
antibodies, a Vectastain elite ABC kit and 3󸀠,3󸀠-diaminoben-
zidine (DAB) substrate kit (Vector Labs, CA, USA) were used
according to the manufacturer’s protocol. As negative control
sections, each primary antibody or the secondary antibody
was omitted. All the slices on the slide glasses were covered
by cover glasses with VECTASHIELD mounting medium
(Vector Labs, CA, USA). They were observed and recorded
with a digital camera-equipped BX51 light microscope
(Olympus, Tokyo, Japan) at a magnitude of 12.5x (cresyl
violet) or 200x (NeuN, Bax, Bcl-2𝛼, and DCX) or 400x (𝛽III-
tubulin, MAP2, Nestin, and Ki67). To detect anti-cleaved
caspase-3 antibody (polyclonal, Bio Vision, CA, USA, 1 : 100),
TSA system with FITC kit (GE Health Science, MA, USA)
combined with Ho¨chst 33258 (Invitrogen, OR, USA) nuclear
staining was used. The images were observed and captured
with LSM510 confocal laser scanning microscope system
(Carl Zeiss, Heidelberg, Germany) at a magnitude of 200x
using ZEN 2009 interface with line mode, 3𝜇m thickness of
pinhole setting, and 4 × averaging with scan speed 4 (2min,
5 sec).
2.6. Analysis of the Immunoreactivity. The images of DG
from 4 slices/animal were captured and analyzed using a
computer-associated image analyzer (WinROOF Version 5;
Mitani Corporation, Fukui, Japan) by an examiner who was
not aware of the grouping details. Images from one slice
were collected from both ipsi- and contralateral DG so that
70% or more of the area of GCL could be examined. We
defined the granular cell layer (GCL) in each image with
100 𝜇m width and SGZ at the inner edge of GCL with 20𝜇m
width and measured the defined area as mm2 automatically
with the analyzer. The number of cresyl violet-stained or
immunopositive cells (NeuN, cleaved caspase-3, Bax, Bcl-2𝛼,
Nestin, Ki67, and DCX) or % immunopositive density (𝛽III-
tubulin and MAP2) in each image was measured, summed
up for 4 slices/animal, and was calculated as per mm2 of the
measured area in each animal.
2.7. Statistical Analysis. All the data are given as means
± standard error of mean (SEM). The following analysis
was used: behavioral examinations, two-way (time, group)
analysis of variance (ANOVA) followed by Scheffe post hoc
test at each time point; immunohistochemical examinations
of the time course analysis, two-way (time, group) ANOVA
followed by Tukey-Kramer post hoc test (Nissl, NeuN, 𝛽III-
tubulin, MAP2, Nestin, Ki67, and DCX) or unpaired 𝑡-test
(cleaved caspase-3, Bax, and Bcl-2𝛼) at each time point;
immunohistochemical examinations with IMP at 30 weeks
after the surgical operation, one-way (group) ANOVA fol-
lowed by Tukey-Kramer post hoc test; comparisons of two
independent groups, unpaired 𝑡-test. 𝑃 < 0.05 was regarded
as statistically significant. All of the analysis was done using
StatView Ver. 5.0 (SAS Institute, USA).
3. Results
3.1. Aggravation of Anhedonia after MCAO. We first exam-
ined whether depression-related behavior anhedonia would
be spontaneously expressed after MCAO in rats. Normal
rats usually show 80–90% of sucrose preference (87.9 ±
2.8% at 30 weeks in sham), as shown in Figures 1(a) and
1(b) (open symbols). MCAO-operated rats (closed symbols)
tended to less prefer sucrose containing water compared to
sham groups (open symbols) throughout the time course
after MCAO. Interestingly, sucrose preference was further
decreased significantly at 20 and 30 weeks after MCAO to
around 50–60% (56.8 ± 4.5% at 30 weeks in MCAO, 𝑃 < 0.01
versus sham), and it was prevented by chronic administration
of IMP (Figure 1(a), 78.9±3.8% at 30 weeks inMCAO+ IMP,
𝑃 < 0.05 versus MCAO) or FLV (Figure 1(b), 76.7 ± 2.2% in
MCAO + FLV at 30 weeks, 𝑃 < 0.05 versus MCAO) signif-
icantly. Daily amount of water consumption was decreased
significantly to around 60% in MCAO-operated rats (59.2 ±
3.3mL in sham versus 33.7 ± 1.8mL in MCAO at 30 weeks,
𝑃 < 0.01) and was not prevented by chronic IMP treatment
(Figure 1(c), 34.4 ± 3.1mL in MCAO + IMP at 30 weeks, 𝑃 >
0.05 versusMCAO).The bodyweight of theMCAO-operated
rats initially decreased significantly (230.1 ± 3.7 g in sham
versus 170.4 ± 5.3 g in MCAO at 3 days, 𝑃 < 0.01) and stayed
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Figure 1: Behavioral analysis of the rats after MCAO. Symbols used are as follows: open square, sham; open circle, sham + antidepressant;
closed square, MCAO; closed circle, MCAO + antidepressant;𝑁 = 10/group, total𝑁 = 40. For antidepressants treatment, vehicle (open and
closed square), 20mg/kg/day of IMP in (a) and (c) to (f) or FLV in (b) (open and closed circles) was administered for 29 weeks. Statistical
significance was evaluated with two-way ANOVA followed by Scheffe post hoc test. (a) Sucrose preference test with IMP. 𝐹
(time) 4 = 17.4;
𝐹
(group) 3 = 63.9; 𝐹(time∗group) 12,180 = 9.131;
∗
𝑃 < 0.05 and ∗∗𝑃 < 0.01 versus sham; ##𝑃 < 0.01 versus MCAO + IMP. (b) Sucrose preference test
with FLV. 𝐹
(time) 4 = 2.76; 𝐹(group) 3 = 39.5; 𝐹(time∗group) 12,180 = 2.13;
∗
𝑃 < 0.05 and ∗∗𝑃 < 0.01 versus sham; ##𝑃 < 0.01 versus MCAO + FLV. (c)
Daily amount of water drinking before (Naı¨ve) and after MCAO. 𝐹
(time) 8 = 27.2; 𝐹(group) 3 = 351.1; 𝐹(time∗group) 24,324 = 9.70;
∗∗
𝑃 < 0.01 versus
sham. (d) Changes of body weight before (Na¨ıve) and after MCAO. 𝐹
(time) 8 = 1291.6; 𝐹(group) 3 = 249.5; 𝐹(time∗group) 24,324 = 11.1;
∗∗
𝑃 < 0.01
versus sham. (e, f) Open field test. (e) Horizontal activity during a period of 10min. 𝐹
(time) 4 = 3.43; 𝐹(group) 3 = 56.8; 𝐹(time∗group) 12,180 = 3.45;
∗∗
𝑃 < 0.01 versus sham. (f) Vertical activity characterized by the number of rearing instances during a period of 10min. 𝐹
(time) 4 = 9.79;
𝐹
(group) 3 = 41.0; 𝐹(time∗group) 12,180 = 1.59;
∗∗
𝑃 < 0.01 versus sham.
Neural Plasticity 5
Sham
(a)
MCAO (ipsilateral)
(b)
MCAO (contralateral)
(c)
Sham + IMP
(d)
MCAO + IMP (ipsilateral)
(e)
MCAO + IMP (contralateral)
(f)
Figure 2: Typical images of the cresyl violet staining in the hippocampal dentate gyrus of rats. Note that the entire shape of GCL in (b)
(ipsilateral MCAO) is shrunk compared to the others. Scale bar indicates 200𝜇m.
lower than sham groups until around 6 weeks after MCAO
and then gradually recovered and was almost the same as
sham group at 30 weeks (Figure 1(d): 487.4 ± 6.2 g in sham
versus 485.2±7.1 g inMCAO at 30 weeks,𝑃 > 0.05). Chronic
IMP treatment did not affect them afterMCAO (465.9±7.3 g
in MCAO + IMP at 30 weeks, 𝑃 > 0.05 versus MCAO). The
rats given FLV also showed similar results to Figures 1(c) and
1(d) (data not shown).
3.2. Spontaneous Activity of the Rats after MCAO. We next
examined the spontaneous activity of rats with open field test
(Figures 1(e) and 1(f)). It revealed that both horizontal and
vertical activities of MCAO-operated rats (closed symbols)
were decreased significantly compared to sham groups (open
symbols). However, they gradually recovered and reached a
similar level to that of sham group at 30 weeks after MCAO
(Figures 1(e) and 1(f): horizontal activity, 103.4 ± 4.3 in sham
versus 77.6 ± 5.8 in MCAO, 𝑃 > 0.05; vertical activity,
30.1 ± 1.2 in sham versus 23.5 ± 2.2 in MCAO, 𝑃 > 0.05).
Chronic IMP treatment did not affect them (Figures 1(e) and
1(f): horizontal activity, 83.2 ± 4.9 in MCAO + IMP, 𝑃 > 0.05
versus MCAO; vertical activity, 24.2 ± 1.8 in MCAO + IMP,
𝑃 > 0.05 versusMCAO). Similar results with FLV-treated rats
were observed (data not shown).
3.3. Specific Loss of the Granular Neurons in the Ipsilateral
DG after MCAO. In the paraffin sections prepared from
the brains at 30 weeks after MCAO, DG of the dor-
sal hippocampus was observed with cresyl violet staining
(Figure 2). We noticed that the shape of GCL was shrunk
specifically in the slices prepared from MCAO-operated
ipsilateral hippocampus (Figure 2(b)). Time course analysis
of the cresyl violet-stained cells revealed the significant loss
of the cells in GCL observed at 20 and 30 weeks after
MCAO (Figure 3(b): 4699.6±119.2 cells/mm2 in sham versus
3561.8 ± 177.3 cells/mm2 in ipsilateral MCAO at 30 weeks,
𝑃 < 0.01), and it was prevented by chronic administration
of IMP from 1 week to 30 weeks after MCAO (Figure 3(c):
4531.0±262.5 cells/mm2 in ipsilateralMCAO+ IMP,𝑃 < 0.05
versus ipsilateral MCAO).
We also quantified the number of the cells in which the
condensed cytosol was observed with cresyl violet staining
at 30 weeks after MCAO (𝐹
5,24
= 1.67, one-way ANOVA
followed by Tukey-Kramer post hoc test). Compared with
sham (102.7±14.7 cells/mm2), MCAO tended to increase the
condensed cells in both ipsi- and contralateral GCL without
statistical significance (147.5 ± 9.6 cells/mm2 in ipsilateral
MCAO and 129.2 ± 16.7 cells/mm2 in contralateral MCAO,
𝑃 > 0.05 versus sham), and IMP did not reverse them
(137.4 ± 14.8 cells/mm2 in ipsilateral MCAO + IMP and
133.2 ± 21.4 cells/mm2 in contralateral MCAO + IMP, 𝑃 >
0.05 versus sham).
Because loss of GC in DG after ischemia had never
been reported yet, we examined NeuN immunoreactivity
as a marker of the matured neurons in GCL (Figure 4).
Similar to the result of cresyl violet staining in Figure 3,
time course analysis revealed that the number of NeuN
immunopositive cells in GCL was decreased at 20 and
30 weeks after MCAO significantly (Figure 4(b): 4401.0 ±
110.4 cells/mm2 in sham versus 3230.9 ± 235.8 cells/mm2 in
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Figure 3: Analysis of the cresyl violet-stained cells in GCL. (a) Typical images of the slices taken at 30 weeks after MCAO. Scale bar indicates
50 𝜇m. (b) Time course changes of Nissl positive cells after MCAO in GCL. Symbols used are as follows: open square, sham; closed triangle,
ipsilateralMCAO; open triangle, contralateralMCAO. Statistical significancewas evaluatedwith two-wayANOVA followed byTukey-Kramer
test at each time point (𝐹
(time) 7 = 2.96; 𝐹(group) 2 = 7.37; 𝐹(time∗group) 14,96 = 2.42;
∗∗
𝑃 < 0.01 versus sham). (c) Analysis of the effect of
IMP on the number of Nissl positive cells at 30 weeks after MCAO. Open columns, sham; hatched columns, ipsilateral MCAO; striped
columns, contralateral MCAO. Vehicle [IMP(−)] or 20mg/kg/day of IMP for 29 weeks [IMP(+)] from 1 week after the surgical operation was
administered. Statistical significance was evaluated with one-way ANOVA followed by Tukey-Kramer test (𝐹
5,24
= 8.78; ∗∗𝑃 < 0.01 versus
sham [IMP(−)]; #𝑃 < 0.05 and ##𝑃 < 0.01 versus ipsilateral MCAO;𝑁 = 5/group).
ipsilateral MCAO at 30 weeks, 𝑃 < 0.01) and the decrease
was prevented by chronic IMP treatment for 29 weeks after
MCAO (Figure 4(c): 4169.8 ± 287.5 cells/mm2 in ipsilateral
MCAO + IMP, 𝑃 < 0.05 versus ipsilateral MCAO).
We further examined other antibodies for the neuronal
markers 𝛽III-tubulin and MAP2 (Figures 5 and 6) in GCL
with measuring % density of the immunoreactive area.
Immunoreactivity of 𝛽III-tubulin in ipsilateral GCL started
Neural Plasticity 7
Sham MCAO (ipsilateral) MCAO (contralateral)
Sham + IMP MCAO + IMP (ipsilateral) MCAO + IMP (contralateral)
Hilus
GCL
Hilus Hilus
GCL
Hilus
GCLGCL
Hilus
GCL
Hilus
GCL
(a)
∗∗
∗∗
1w 2w 6w1d 3d 20w 30wNaïve
N
um
be
r o
f c
el
ls/
m
m
2
2500
3000
3500
4000
4500
5000
5500
(b)
∗∗
IMP(−) IMP(+)
#
#
N
um
be
r o
f c
el
ls/
m
m
2
2000
2500
3000
3500
4000
4500
5000
5500
(c)
Figure 4: Analysis of NeuN immunopositive cells in GCL. (a) Typical images of the slices taken at 30 weeks after MCAO. Scale bar indicates
50 𝜇m. (b) Time course changes of NeuN immunopositive cells after MCAO in GCL. Symbols used are as follows: open square, sham; closed
triangle, ipsilateral MCAO; open triangle, contralateral MCAO. Statistical significance was evaluated with two-way ANOVA followed by
Tukey-Kramer test at each time point (𝐹
(time) 7 = 2.78; 𝐹(group) 2 = 11.0; 𝐹(time∗group) 14,96 = 1.57;
∗∗
𝑃 < 0.01 versus sham). (c) Analysis of the
effect of IMP on the number of NeuN immunopositive cells at 30 weeks after MCAO. Vehicle [IMP(−)] or 20mg/kg/day of IMP for 29 weeks
[IMP(+)] from 1 week after the surgical operation was administered. Statistical significance was evaluated with one-way ANOVA followed by
Tukey-Kramer test (𝐹
5,24
= 7.00; ∗∗𝑃 < 0.01 versus sham [IMP(−)]; #𝑃 < 0.05 versus ipsilateral MCAO [IMP(−)];𝑁 = 5/group).
to decrease at 6 weeks afterMCAO (Figure 5(b): 18.8±0.90%
in sham versus 14.6 ± 0.61% in ipsilateral MCAO, 𝑃 < 0.05)
and further decreased at 20 and 30 weeks (12.4 ± 0.48%,
𝑃 < 0.01 versus sham), and it was reversed by chronic IMP
treatment (15.7 ± 0.72%, 𝑃 < 0.01). Similar results were
obtained from the examination of MAP2 immunoreactivity
(Figure 6). At 30 weeks after the surgical operation, 19.6 ±
0.50% in sham was decreased to 14.2 ± 0.51% in ipsilateral
MCAO (𝑃 < 0.01), and chronic IMP treatment prevented it
(17.0 ± 1.20%, 𝑃 > 0.05 versus sham).
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Figure 5: Analysis of 𝛽III-tubulin immunopositive areas in GCL. (a) Typical images of the slices taken at 30 weeks after MCAO. Scale bar
indicates 30 𝜇m. (b)Time course changes of𝛽III-tubulin immunopositive areas afterMCAO inGCL. Symbols used are as follows: open square,
sham; closed triangle, ipsilateral MCAO; open triangle, contralateral MCAO. Statistical significance was evaluated with two-way ANOVA
followed by Tukey-Kramer test at each time point (𝐹
(time) 7 = 3.06; 𝐹(group) 2 = 19.6; 𝐹(time∗group) 14,96 = 1.17;
∗
𝑃 < 0.05 and ∗∗𝑃 < 0.01 versus
sham). (c) Analysis of the effect of IMP on 𝛽III-tubulin immunopositive areas at 30 weeks after MCAO. Vehicle [IMP(−)] or 20mg/kg/day
of IMP for 29 weeks [IMP(+)] from 1 week after the surgical operation was administered. Statistical significance was evaluated with one-way
ANOVA followed by Tukey-Kramer test (𝐹
5,24
= 6.05; ∗∗𝑃 < 0.01 versus sham [IMP(−)];𝑁 = 5/group). Unpaired 𝑡-test was performed with
ipsilateral MCAO [IMP(−)] versus contralateral MCAO [IMP(−)] (𝑡 = 3.41, $$𝑃 < 0.01) or versus ipsilateral MCAO [IMP(+)] (𝑡 = 4.12,
$$
𝑃 < 0.01).
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Figure 6: Analysis of MAP2 immunopositive areas in GCL. (a) Typical images of the slices taken at 30 weeks afterMCAO. Scale bar indicates
20 𝜇m. (b) Time course changes of MAP2 immunopositive areas after MCAO in GCL. Symbols used are as follows: open square, sham;
closed triangle, ipsilateral MCAO; open triangle, contralateral MCAO. Statistical significance was evaluated with two-way ANOVA followed
by Tukey-Kramer test at each time point (𝐹
(time) 7 = 11.0; 𝐹(group) 2 = 16.1; 𝐹(time∗group) 14,96 = 3.65;
∗∗
𝑃 < 0.01 versus sham). (c) Analysis of the
effect of IMP onMAP2 immunopositive areas at 30 weeks afterMCAO.Vehicle [IMP(−)] or 20mg/kg/day of IMP for 29weeks [IMP(+)] from
1 week after the surgical operation was administered. Statistical significance was evaluated with one-way ANOVA followed by Tukey-Kramer
test (𝐹
5,24
= 5.07; ∗∗𝑃 < 0.01 versus sham [IMP(−)]; #𝑃 < 0.05 versus ipsilateral MCAO [IMP(−)];𝑁 = 5/group).
All of these data indicated the degenerative loss of GC in
the ipsilateral DG at chronic stages after MCAO.
3.4. Increased Apoptosis in GCL after MCAO. In Section 3.3,
we showed that delayed neuronal loss occurred in the
ipsilateral GCL of the hippocampal DG at chronic stages after
MCAO. To examine whether the degenerative loss of GC
involved neuronal apoptosis, we next performed immunos-
taining of cleaved caspase-3, which executes apoptosis. We
analyzed the ipsilateral GCL and SGZ separately to distin-
guish the matured neurons and the other cells including
NSCs in DG. In GCL, the number of cleaved caspase-3
immunopositive cells was significantly increased at 2 through
30 weeks of MCAO (Figure 7(b): 17.7 ± 1.44 cells/mm2 in
sham versus 55.1±4.76 cells/mm2 inMCAO at 30 weeks, 𝑃 <
0.01) and the decrease was mostly prevented by chronic IMP
treatment at 30 weeks after MCAO (Figures 7(a) and 7(d):
19.8 ± 1.01 cells/mm2 in MCAO + IMP at 30 weeks, 𝑃 < 0.01
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Figure 7: Analysis of the number of cleaved caspase-3 immunopositive cells in ipsilateral GCL and SGZ. (a) Typical images of the slices
taken at 30 weeks after MCAO. Blue signal is the nuclei stained with Ho¨chst 33258, while green signal of FITC is from cleaved caspase-3
immunopositive cells. Scale bar indicates 50𝜇m. (b, c) Time course changes of cleaved caspase-3 immunopositive cells after MCAO in GCL
(b) and SGZ (c). Symbols used are as follows: open square, sham; closed triangle, MCAO. Statistical significance was evaluated with two-
way ANOVA followed by unpaired 𝑡-test at each time point (GCL: 𝐹
(time) 7 = 21.2, 𝐹(group) 1 = 129.6, 𝐹(time∗group) 7,64 = 19.1, 𝑡(2w) = 3.71,
𝑡
(6w) = 12.35, 𝑡(20w) = 6.24, and 𝑡(30w) = 7.53; SGZ: 𝐹(time) 7 = 4.50, 𝐹(group) 1 = 5.84, 𝐹(time∗group) 7,64 = 6.06, 𝑡(3 d) = 3.29, 𝑡(6w) = −2.79,
𝑡
(20w) = −4.86, and 𝑡(30w) = −3.95;
∗
𝑃 < 0.05 and ∗∗𝑃 < 0.01 versus sham). (d, e) Analysis of the effect of IMP (20mg/kg/day for 29 weeks) on
the number of cleaved caspase-3 immunopositive cells at 30 weeks afterMCAO in GCL (d) and SGZ (e). Statistical significance was evaluated
with one-way ANOVA followed by Tukey-Kramer post hoc test (𝐹
(GCL) 3,16 = 24.63; 𝐹(SGZ) 3,16 = 18.41;
∗∗
𝑃 < 0.01 versus sham [IMP(−)];
##
𝑃 < 0.01 versus MCAO [IMP(−)];𝑁 = 5/group).
versus MCAO). In contrast, the number of cleaved caspase-3
immunopositive cells in SGZ was initially increased at 3 days
(49.3 ± 3.03 cells/mm2 in sham versus 65.1 ± 3.71 cells/mm2
in MCAO, 𝑃 < 0.05) and then decreased at 6 through 30
weeks of MCAO (Figure 7(c): 52.3 ± 3.73 cells/mm2 in sham
versus 32.2±3.48 cells/mm2 inMCAO at 30 weeks,𝑃 < 0.01),
and chronic IMP treatment tended to prevent it (Figure 7(e):
40.6±1.79 cells/mm2,𝑃 > 0.05 versus sham). It is notable that
the number of cleaved caspase-3 immunopositive cells in SGZ
was much higher than that of GCL in sham groups, whereas
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Figure 8: Analysis of the number of Bax immunopositive cells in the ipsilateral GCL and SGZ. (a) Typical images of the slices taken at 30
weeks after MCAO. Scale bar indicates 50 𝜇m. (b, c) Time course changes of Bax immunopositive cells after MCAO in GCL (b) and SGZ (c).
Symbols used are as follows: open square, sham; closed triangle,MCAO. Statistical significance was evaluated with two-way ANOVA followed
by unpaired 𝑡-test at each time point (GCL: 𝐹
(time) 7 = 18.1, 𝐹(group) 1 = 286.4, 𝐹(time∗group) 7,64 = 19.3, 𝑡(1 d) = 12.8, 𝑡(1w) = 2.46, 𝑡(2w) = 5.61,
𝑡
(6w) = 6.30, 𝑡(20w) = 11.3, and 𝑡(30w) = 7.95; SGZ: 𝐹(time) 7 = 11.2, 𝐹(group) 1 = 27.8, 𝐹(time∗group) 7,64 = 12.3, 𝑡(1 d) = 7.51, 𝑡(3 d) = 5.52, 𝑡(2w) = 3.17,
and 𝑡
(30w) = −2.00;
∗
𝑃 < 0.05 and ∗∗𝑃 < 0.01 versus sham). (d, e) Analysis of the effect of IMP (20mg/kg/day for 29 weeks) on the number
of Bax immunopositive cells at 30 weeks after MCAO in GCL (d) and SGZ (e). Statistical significance was evaluated with one-way ANOVA
followed by Tukey-Kramer post hoc test (𝐹
(GCL) 3,16 = 31.1; 𝐹(SGZ) 3,16 = 6.07;
∗
𝑃 < 0.05 and ∗∗𝑃 < 0.01 versus sham [IMP(−)];𝑁 = 5/group).
it was reversed after 20 and 30 weeks of MCAO, suggesting
the increased apoptosis of the matured GC and decreased
apoptosis of NSCs in DG after MCAO.
3.5. Analysis of the Death and Survival Signaling in DG after
MCAO. Related to the increased apoptosis in the ipsilateral
GCL, we characterized the immunoreactivities of Bax as a
marker of death signaling and Bcl-2𝛼 as a marker of survival
signaling in DG using specific antibodies for them (Figures
8 and 9, Supplementary Figures 1 and 2 in Supplementary
Material available online at http://dx.doi.org/10.1155/2016/
5054275).
In the ipsilateral GCL, Bax immunoreactivity increased
transiently at 1 day afterMCAO (Figure 8(b): 11.9±2.23 cells/
mm2 in sham versus 53.7 ± 2.38 cells/mm2 in MCAO,
𝑃 < 0.01), returned to the sham level in 3 days, and then
increased again and stayed higher than the sham group
significantly at 1 through 30 weeks of MCAO (Figure 8(b):
14.7 ± 2.47 cells/mm2 in sham versus 57.4 ± 4.78 cells/mm2
in MCAO at 30 weeks, 𝑃 < 0.01). The increased Bax was not
12 Neural Plasticity
GCL
SGZ
Sham
GCL
SGZ
MCAO
GCL
SGZ
GCL
SGZ
Sham + IMP MCAO + IMP
(a)
1d 3d 1w 2w 6w 20w 30wNaïve
∗∗
∗∗
∗∗
∗∗
∗∗
∗
∗
N
um
be
r o
f c
el
ls/
m
m
2
0
50
100
150
200
250
(b)
1w 2w 6w1d 3d 20w 30wNaïve
∗∗
∗∗
∗∗
∗
N
um
be
r o
f c
el
ls/
m
m
2
0
50
100
150
200
250
(c)
Sham Sham + IMP MCAO MCAO + IMP
0
10
20
30
40
50
60
70
∗∗
##
N
um
be
r o
f c
el
ls/
m
m
2
(d)
Sham Sham + IMP MCAO MCAO + IMP
N
um
be
r o
f c
el
ls/
m
m
2
0
10
20
30
40
50
60
70
(e)
Figure 9: Analysis of the number of Bcl-2𝛼 immunopositive cells in the ipsilateral GCL and SGZ. (a) Typical images of the slices taken
at 30 weeks after MCAO. Scale bar indicates 50𝜇m. (b, c) Time course changes of Bcl-2𝛼 immunopositive cells after MCAO in GCL (b)
and SGZ (c). Symbols used are as follows: open square, sham; closed triangle, MCAO. Statistical significance was evaluated with two-way
ANOVA followed by unpaired 𝑡-test at each time point (GCL: 𝐹
(time) 7 = 40.3, 𝐹(group) 1 = 20.8, 𝐹(time∗group) 7,64 = 48.7, 𝑡(1 d) = 12.4, 𝑡(3 d) = 3.15,
𝑡
(1w) = −5.54, 𝑡(2w) = 3.31, 𝑡(6w) = −4.16, 𝑡(20w) = −5.73, and 𝑡(30w) = −5.44; SGZ: 𝐹(time) 7 = 23.1, 𝐹(group) 1 = 2.36, 𝐹(time∗group) 7,64 = 18.2,
𝑡
(1 d) = 7.36, 𝑡(1w) = −5.38, 𝑡(2w) = 2.90, and 𝑡(6w) = −3.64;
∗
𝑃 < 0.05 and ∗∗𝑃 < 0.01 versus sham). (d, e) Analysis of the effect of IMP
(20mg/kg/day for 29 weeks) on the number of Bcl-2𝛼 immunopositive cells at 30 weeks after MCAO in GCL (d) and SGZ (e). Statistical
significance was evaluated with one-way ANOVA followed by Tukey-Kramer post hoc test (𝐹
(GCL) 3,16 = 11.9; 𝐹(SGZ) 3,16 = 1.84;
∗∗
𝑃 < 0.01
versus sham [IMP(−)]; ##𝑃 < 0.01 versus MCAO;𝑁 = 5/group).
prevented by chronic IMP treatment at 30 weeks afterMCAO
(Figure 8(d): 47.8±5.29 cells/mm2 inMCAO+ IMP,𝑃 < 0.01
versus sham). In the ipsilateral SGZ, Bax immunoreactivity
showed a biphasic increase with its initial peak at 1–3 days
(Figure 8(c): 77.7 ± 3.52 cells/mm2 at 1 day, 𝑃 < 0.01) and
the second peak at 2 weeks (49.4 ± 5.70 cells/mm2, 𝑃 < 0.05)
and then returned to the sham level and was lower than sham
at 30 weeks after MCAO (24.5 ± 2.97 cells/mm2, 𝑃 < 0.05).
Chronic IMP treatment tended to prevent this decrease at 30
weeks (Figure 8(e): 34.8 ± 4.66 cells/mm2, 𝑃 > 0.05 versus
sham). The same analysis was performed in the contralateral
DG (Supplementary Figure 1). Different from the ipsilateral
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Figure 10: Time course changes of Bax/Bcl-2𝛼 index inGCL (a) and SGZ (b). Symbols used are as follows: open square, sham; closed triangles,
ipsilateral MCAO; open triangles, contralateral MCAO.
GCL, Bax immunoreactivity in the contralateral GCL only
showed the initial increase at 1 day (Supplementary Figure 1B:
16.7 ± 2.98 cells/mm2 in sham versus 61.9 ± 5.38 cells/mm2
in MCAO, 𝑃 < 0.01) and returned to the basal level at
3 days through 30 weeks after MCAO, and chronic IMP
treatment had no effect on it (Supplementary Figure 1D).The
contralateral SGZ showed a similar time course change to the
ipsilateral SGZ, although it only had a significant increase
at 1 and 3 days after MCAO (Supplementary Figure 1C:
28.5±4.31 cells/mm2 in sham versus 73.31±3.80 cells/mm2 in
MCAO at 1 day, 𝑃 < 0.01) and returned to the sham level at 1
week through 30 weeks afterMCAO. Chronic IMP treatment
had no effect on it (Supplementary Figure 1E).
Immunoreactivity of Bcl-2𝛼 in the ipsilateral GCL
(Figure 9(b): 47.0 ± 1.50 cells/mm2 in sham throughout the
time course) showed a biphasic increase with two peaks
at 1 day (182.4 ± 10.7 cells/mm2, 𝑃 < 0.01) and 2 weeks
(79.4 ± 8.99 cells/mm2, 𝑃 < 0.05) after MCAO. However, it
was significantly lower than sham at 1, 6, 20, and 30 weeks
(22.8 ± 2.04 cells/mm2 at 30 weeks, 𝑃 < 0.01), and chronic
IMP treatment normalized it at 30 weeks (Figure 9(d): 52.2 ±
2.15 cells/mm2, 𝑃 < 0.05 versus MCAO). Similar time course
change of Bcl-2𝛼 to GCL was observed in the ipsilateral SGZ
with two peaks at 1 day (121.6 ± 7.11 cells/mm2, 𝑃 < 0.01)
and 2 weeks (85.2 ± 6.38 cells/mm2, 𝑃 < 0.05) after MCAO
(Figure 9(c)). As was in GCL, it was significantly lower than
sham at 1 and 6 weeks, although it returned to the sham
level at 20 and 30 weeks after MCAO, and there was no
difference between sham andMCAO groups with or without
IMP (Figure 9(e)). In the contralateral GCL (Supplementary
Figure 2B: 45.9 ± 1.68 cells/mm2 throughout the time course
in sham), it also showed a biphasic increase with two peaks at
1 day (268.1 ± 6.60 cells/mm2, 𝑃 < 0.01) and 2 weeks (139.3 ±
25.2 cells/mm2,𝑃 < 0.01). Different from the ipsilateral GCL,
it never dropped below the sham level throughout the time
course. At 30 weeks after MCAO, there was no significant
difference between sham andMCAOwith or without chronic
IMP treatment (Supplementary Figure 2D). Similar result
was obtained from the contralateral SGZ (Supplementary
Figures 2C and 2E).
From these results of Bax and Bcl-2𝛼, we calculated
Bax/Bcl-2𝛼 ratio [38] to see how the death and the survival
signaling were changed after MCAO in GCL and in SGZ
(Figure 10). In the ipsilateral GCL (Figure 10(a), closed tri-
angle), it exceeded 1.0 at 6 through 30 weeks after MCAO,
suggesting that the death signaling was dominant in chronic
stages. In contrast, the index in SGZ (Figure 10(b)) increased
at early stages after MCAO, exceeded 1.0 at 3 days and 1 week,
and returned to the normal level at 2 through 30 weeks after
MCAO. In the contralateral GCL and SGZ (open triangle), it
kept below 1.0 as was in sham (open square) throughout the
time course for 30 weeks after MCAO.
3.6. Analysis of Neural Stem Cell Proliferation and Develop-
ment in SGZ after MCAO. We further analyzed the pro-
liferation and development of NSCs in SGZ because they
are well related to mood, depressiveness, and effects of
antidepressants.
InMCAO rats, immunoreactivity of NSCsmarker Nestin
increased transiently at 3 days and 1week afterMCAO in both
the ipsilateral and contralateral SGZ of DG (Figure 11(b) at 3
days: 58.4±4.13 cells/mm2 in sham; 101.4±7.55 cells/mm2 in
ipsilateral SGZ, 𝑃 < 0.01 versus sham; 88.4 ± 7.18 cells/mm2
in contralateral SGZ, 𝑃 < 0.05 versus sham) and then
decreased and reached almost 50% of sham group (at 30
weeks: 29.9 ± 2.12 cells/mm2 in ipsilateral MCAO, 𝑃 < 0.01
versus sham; 36.1 ± 3.5 cells/mm2 in contralateral MCAO,
𝑃 < 0.01 versus sham). Chronic IMP treatment for 29 weeks
significantly prevented the decrease of Nestin-positive cells
observed in ipsilateral MCAO group at 30 weeks (39.9 ±
1.47 cells/mm2, 𝑃 < 0.05 versus MCAO), although they
were still lower than those of sham group significantly
(Figure 11(c)).
We also examined Ki67 immunoreactivity as a prolifer-
ating cell marker. The result was similar to those observed
in Nestin. Ki67 immunoreactivity increased transiently with
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Figure 11: Analysis of Nestin immunopositive cells in GCL. (a) Typical images of the slices taken at 30 weeks after MCAO. Scale bar indicates
20 𝜇m. (b) Time course changes of Nestin immunopositive cells after MCAO in GCL. Symbols used are as follows: open square, sham; closed
triangle, ipsilateral MCAO; open triangle, contralateral MCAO. Statistical significance was evaluated with two-way ANOVA followed by
Tukey-Kramer test at each time point (𝐹
(time) 7 = 53.9; 𝐹(group) 2 = 0.097; 𝐹(time∗group) 14,96 = 12.5;
∗
𝑃 < 0.05 and ∗∗𝑃 < 0.01 versus sham).
(c) Analysis of the effect of imipramine (IMP) on the number of Nestin immunopositive cells at 30 weeks after MCAO. Vehicle [IMP(−)] or
20mg/kg/day of IMP for 29 weeks [IMP(+)] from 1 week after the surgical operation was administered. Statistical significance was evaluated
with one-way ANOVA followed by Tukey-Kramer test (𝐹
5,24
= 11.36; ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01 versus sham [IMP(−)]; 𝑁 = 5/group).
Unpaired 𝑡-test was performed with ipsilateral MCAO [IMP(−)] versus [IMP(+)] (𝑡 = −2.40, $𝑃 < 0.05).
its peak at 3 days after MCAO (Figure 12(b) at 3 days:
50.4 ± 6.29 cells/mm2 in sham; 175.9 ± 12.8 cells/mm2 in
ipsilateral SGZ, 𝑃 < 0.01 versus sham; 90.1 ± 5.12 cells/mm2
in contralateral SGZ, 𝑃 < 0.05 versus sham) and then
decreased and stayed with a few cells per mm2 at 6 through
30 weeks (Figure 12(b) at 30 weeks: 6.40 ± 0.79 cells/mm2
in ipsilateral MCAO, 𝑃 < 0.01 versus sham; 8.51 ±
2.55 cells/mm2 in contralateral MCAO, 𝑃 < 0.01 versus
sham). Chronic IMP treatment significantly prevented the
decreased Ki67 immunoreactivity at 30 weeks afterMCAO in
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Figure 12: Analysis of Ki67 immunopositive cells in GCL. (a) Typical images of the slices taken at 30 weeks after MCAO. Scale bar indicates
20 𝜇m. (b) Time course changes of Ki67 immunopositive cells after MCAO in GCL. Symbols used are as follows: open square, sham; closed
triangle, ipsilateral MCAO; open triangle, contralateral MCAO. Statistical significance was evaluated with two-way ANOVA followed by
Tukey-Kramer test at each time point (𝐹
(time) 7 = 101.1; 𝐹(group) 2 = 38.2; 𝐹(time∗group) 14,96 = 37.7;
∗∗
𝑃 < 0.01 versus sham). (c) Analysis of
the effect of imipramine (IMP) on the number of Ki67 immunopositive cells at 30 weeks after MCAO. Vehicle [IMP(−)] or 20mg/kg/day of
IMP for 29 weeks [IMP(+)] from 1 week after the surgical operation was administered. Statistical significance was evaluated with one-way
ANOVA followed by Tukey-Kramer test (𝐹
5,24
= 29.53; ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01 versus sham [IMP(−)]; #𝑃 < 0.05 versus contralateral
MCAO [IMP(−)]; 𝑁 = 5/group). Unpaired 𝑡-test was performed with sham [IMP(−)] versus [IMP(+)] (𝑡 = −2.53, $𝑃 < 0.05) or with
ipsilateral MCAO [IMP(−)] versus [IMP(+)] (𝑡 = −4.74, $$𝑃 < 0.01).
all groups, although theywere still around 50%of shamgroup
(Figure 12(c): 16.5 ± 1.98 cells/mm2 in ipsilateral MCAO +
IMP; 24.1 ± 6.05 cells/mm2 in contralateral MCAO + IMP;
𝑃 < 0.05 versus its corresponding MCAO).
Finally, we examined DCX immunoreactivity as a devel-
opmental marker of neurons in GCL. Although we ana-
lyzed entire GCL, most of the immunopositive cells are
found around SGZ. As was observed in Nestin and Ki67,
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Figure 13: Analysis of DCX immunopositive cells in GCL. (a) Typical images of the slices taken at 30 weeks after MCAO. Scale bar indicates
50 𝜇m. (b) Time course changes of DCX immunopositive cells after MCAO in GCL. Symbols used are as follows: open square, sham; closed
triangle, ipsilateral MCAO; open triangle, contralateral MCAO. Statistical significance was evaluated with one-way ANOVA followed by
Tukey-Kramer test at each time point (𝐹
(time) 7 = 80.7; 𝐹(group) 2 = 5.91; 𝐹(time∗group) 14,96 = 22.7;
∗∗
𝑃 < 0.01 versus sham; #𝑃 < 0.05 versus
contralateral MCAO [IMP(−)];𝑁 = 5/group). (c) Analysis of the effect of imipramine (IMP) on the number of DCX immunopositive cells
at 30 weeks after MCAO. Vehicle [IMP(−)] or 20mg/kg/day of IMP for 29 weeks [IMP(+)] from 1 week after the surgical operation was
administered. Statistical significance was evaluated with one-way ANOVA followed by Tukey-Kramer test (𝐹
5,24
= 41.60; ∗∗𝑃 < 0.01 versus
sham; #𝑃 < 0.05 versus contralateralMCAO [IMP(−)];𝑁 = 5/group). Unpaired 𝑡-test was performedwith ipsilateralMCAO [IMP(−)] versus
[IMP(+)] (𝑡 = −4.10, $$𝑃 < 0.01).
it also increased in early stages with its peak at 1 week
(Figure 13(b) at 1 week: 58.2±3.39 cells/mm2 in sham; 124.9±
5.54 cells/mm2 in ipsilateral SGZ; 97.5 ± 5.36 cells/mm2 in
contralateral SGZ, 𝑃 < 0.01 versus sham) and then decreased
and stayed lower than sham significantly at 6 through
30 weeks after MCAO (Figure 13(b) at 30 weeks: 14.4 ±
2.21 cells/mm2 in ipsilateral MCAO; 14.8 ± 1.30 cells/mm2
in contralateral MCAO, 𝑃 < 0.01 versus sham). Chronic
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IMP treatment significantly prevented the decreased DCX
immunoreactivity at 30 weeks in MCAO groups, although
they were not normalized as sham group (Figure 13(c):
26.2 ± 1.83 cells/mm2 in ipsilateral MCAO + IMP; 29.1 ±
3.84 cells/mm2 in contralateral MCAO + IMP; 𝑃 < 0.05
versus its corresponding MCAO).
4. Discussion
Here we characterized a possible animal model of the
postischemic depression after the transient MCAO in rats
with a behavioral and an immunohistochemical analysis.
Our findings in this study are as follows: (i) we observed
spontaneous aggravation of anhedonia in MCAO-operated
rats at chronic stages (20 and 30 weeks) after MCAO, which
was prevented by chronic IMP or FLV treatment; (ii) this
aggravation of anhedonia associated with delayed neuronal
death of the granular neurons specifically in the ipsilateral
DG, suggesting it would be a part of cellular and molecular
pathophysiological mechanisms; (iii) the increased prolifera-
tion of NSCs and the following neural development in SGZ
at early stages after MCAO were decreased significantly at
chronic stages with almost ceasedNSCs proliferation; (iv) the
neurodegenerative changes in DGwere prevented by chronic
IMP treatment.
In the following, we discuss these subjects in further
detail.
4.1. Postischemic Anhedonia in MCAO Rodents. From many
previous studies combining MCAO and additional stressor
in rodents [14], it is strongly suggested that the stress vulner-
ability after stroke is increased significantly. Without adding
any contemplated stress, Boyko et al. reported % sucrose
preference in permanent MCAO rats (operated on at 20
weeks of age and examined at 3weeks afterMCAO)decreased
to around 60%, together with the increased immobility in
FST and decreased responses in the shuttle avoidance task
[39]. Craft and DeVries reported that the transient ischemia
model of mice showed anhedonia with around 50% sucrose
preference at 7 days after the surgical operation and was res-
cued by administration of an antagonist of interleukin-1 (IL-
1) receptor [37]. Although both of them did not examine the
time course change of anhedonia nor effect of antidepressants
on it, these reports with our results in Figures 1(a) and 1(b)
showed that PSD in rodents could be induced after MCAO
without combining extra stressor stimuli. Sensitivity of the
experimental anhedonia to antidepressants should carefully
be examined because as shown in Figures 1(a) and 1(b), lessor
sucrose preference in MCAO rats was observed throughout
the time course from 1 day to 6 weeks after MCAO, and it
was insensitive to IMP or FLV. It should also be noted that
the decreased amount of daily water consumption in MCAO
rats was not rescued by IMP nor by FLV, suggesting that
some hypothalamic functions controlling water intake may
be affected after MCAO. Because of this reason, we had to
increase the concentration of antidepressants in the drinking
water of MCAO rats so that they take the same amount
of antidepressants as sham rats. To avoid this issue, use of
an osmotic minipump, for example, would be examined in
further studies.
4.2. Postischemic Neuronal Loss and Apoptosis in GCL. As
mentioned in the Introduction, delayed neuronal death of
the hippocampal CA1 pyramidal neurons after ischemia has
been well characterized, and other regions such as CA3 and
DG were thought to be resistant to ischemic stress. In this
study, however, we demonstrated delayed neuronal death of
the granular neurons in DG at chronic stages afterMCAO for
the first time, which was consistent with the time course of
the aggravation of anhedonia (Figures 1(a), 2–6). Considering
the increased immunoreactivities of cleaved caspase-3 and
Bax together with decreased Bcl-2𝛼 at chronic stages in the
ipsilateral GCL (Figures 7–9), it seems that the death signal
exceeded the survival signal in GCL after 1 week of MCAO
(Figure 10), resulting in the increased apoptotic neuronal
death of the matured GC. The increased Bax after 1 week
stayed higher than that of sham, whereas Bcl-2𝛼 significantly
decreased compared to sham in those periods, suggesting that
the death signal exceeded the survival signal. Further studies
are required to identify what kind ofmolecular factor triggers
this neurodegenerative condition. One possible mechanism
is the increase of the inflammatory factors such as tumor-
necrosis factor 𝛼 (TNF𝛼), IL-1𝛽, IL-6, and iNOS from glial
cells [22, 40, 41]. In fact, trimethyltin was reported to induce
selective loss of granular neurons in DG with activating
TNF𝛼-mediated apoptotic signaling [42, 43]. Other possible
molecular candidates are the decreased trophic factors such
as brain-derived neurotrophic factor (BDNF), nerve growth
factor (NGF) [44, 45], and vascular endothelial growth factor
(VEGF) [46]. BDNF expression in PSD animals has been
examined by researchers [14, 18, 39]. Considering the neu-
ronal activity-dependent production of neurotrophic factors
[47], it is also possible that the brain areas innervating
DG such as the entorhinal cortex might be damaged after
MCAO with decreasing the neuronal input to DG; thus
it reduced the neuronal activities of DG, resulting in the
loss of neurotrophic conditions. Further electrophysiologi-
cal, neurochemical, and immunohistochemical examinations
will explore the detailed pathological mechanisms of the
neurodegeneration in the ipsilateral DG after MCAO.
4.3. Postischemic Proliferation of the Neural Stem Cells in SGZ.
Increased proliferation of NSCs after ischemic event in SGZ
was reported previously [25, 26]. It was also indicated that
the proliferated NSCs differentiated into mature neurons and
integrated inGCL [48]. In fact, our results ofNestin, Ki67, and
DCX immunostaining at early stages after MCAO (Figures
11–13)were consistentwith these reports. Although this initial
increase is thought to be important to keep the number of
mature GC after MCAO for at least 20 weeks, it did not
last for 2 weeks and dropped under the sham levels after
6 weeks of MCAO in our observations (Figures 11–13). It
seemed that NSCs in SGZ after 6 weeks of MCAO escaped
from cell cycle and stayed quiescent.The decreased apoptosis
in SGZ after 20 weeks of MCAO also supports this idea
(Figures 7 and 8). Different from the loss of GC specifically
observed in the ipsilateral GCL, time course changes of NSCs
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were observed in both ipsi- and contralateral sides of SGZ,
suggesting that they were controlled by systemic regulatory
mechanisms such as glucocorticoids released according to
the activation of hypothalamic-pituitary-adrenal (HPA) axis
[49]. GC with condensed cytosol stained by cresyl violet
also tended to increase in both ipsi- and contralateral DG
(see Section 3.3, 2nd paragraph). Together with the apoptotic
loss of the ipsilateral GC, the suppressed neurogenesis of the
bilateral SGZ would also contribute to the aggravation of
anhedonia as a result of response to the psychogenic stressor
triggered by such motor impairments.
4.4. Effects of Antidepressants after MCAO. Because both
IMP and FLV prevented aggravation of anhedonia after 20
weeks of MCAO (Figure 1), we confirmed it was closely
related to PSD. FLV is a SSRI, which primarily increases
serotonin and dopamine together with stimulating sigma-1
receptor [50]. Recent study of Zhang et al. showed decreased
sucrose preference, increased immobility in forced swim
and tail suspension tests, and exacerbated neurological func-
tions with reduced body weight by combining MCAO and
spatial restraint stress in mice [18]. They also showed the
decreased serotonin and dopamine levels in hypothalamus,
hippocampus, and cortex in their PSD mice, which were
reversed by chronic IMP treatment. Thus, PSD is thought to
imply decreased serotonin and dopamine levels in brain with
increased cortisol level in serum.
Based on the results of Bax and Bcl-2𝛼 analysis shown in
Figures 8 and 9, chronic IMP treatment seemed to stimulate
the survival signal rather than suppressing the death signal in
GCL.Neuroprotective effect of antidepressants was suggested
to mediate BDNF-cyclic AMP responsive element-binding
(CREB) protein pathway in a previous report [51], and this
could be one possible molecular mechanism to keep GC alive
by antidepressants after MCAO. Antidepressants including
IMP and FLV are also known to stimulate proliferation
of NSCs in SGZ, thus promoting the increase of adult
neurogenesis [27]. It is understood to be one of the essential
mechanisms for the effects of antidepressants [52]. In fact, our
results in Figures 11–13 showed that IMP tended to stimulate
the proliferation ofNSCs, although it did not normalize to the
sham level in MCAO groups in our experimental condition.
Considering our time course data of both apoptosis and neu-
rogenesis with the effect of antidepressants, favorable timing
for the onset of antidepressant treatment on PSD seems to be
within 2 weeks after MCAO, although it should be carefully
examined with considering the species difference between
rodents and humans. Moreover, effects of antidepressants
after establishing anhedonia should be examined in our
future study, because it will clarify whether antidepressants
have therapeutic potency in addition to neuroprotective
effects in our PSD model.
5. Conclusions
Spontaneous aggravation of anhedonia was observed at the
chronic stage in a rat model of transient cerebral focal
ischemia. It associated with the neurodegenerative changes
in the hippocampal dentate gyrus: apoptotic neuronal loss of
the granular cells and decreased proliferation of the neural
stem cells. They are prevented by chronic administration of
antidepressants. Our study provides new insights into the
pathophysiologicalmechanisms of poststroke depression and
effective use of antidepressants on it.
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